,

Cell Therapies presentations from ISCT

June 7, 2023

Prescient was pleased to present data on our cell therapies at the prestigious International Society of Cell & Gene Therapy (ISCT) conference in Paris in June 2023.

Senior VP of Scientific Affairs at Prescient, Dr Rebecca Lim, and post-doctoral scientist at the Peter MacCallum Cancer Centre, Dr Kevin Sek, presented preclinical data on next-gen modular, controllable CAR platform, OmniCAR, and cell therapy enhancement platform, CellPryme.

The posters presented at ISCT are below.

OmniCAR ISCT Poster 2023
CellPryme ISCT Poster 2023
ISCT Cell Therapy June 2023

Related Post

This investor centre was built by Reach Markets

©2022 Reach Markets

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
×

Any advice is general only

Any advice provided by Reach Markets, the Lead Manager on this offer, including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice.

×

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.